Experts say that a cultural change in industry is needed to get drug makers to focus more on precision dosing for drugs, and that both FDA and payers could help push industry in that direction. FDA could actively encourage individualized dosing in clinical trials rather than a one-size-fits-all approach. And a move to outcomes-based pricing could spur drug makers to conduct such trials so they that don’t lose money if some patients are later found to do well on lower...